Karen Uhlmann
Fondatore presso OMEICOS Therapeutics GmbH
Profilo
Karen Uhlmann is the founder.
She founded OMEICOS Therapeutics GmbH in 2013 and holds the title of Vice President-Operations & IP.
Dr. Uhlmann has a graduate degree from Freie Universität Berlin and a doctorate degree from Humboldt-Universität zu Berlin.
Posizioni attive di Karen Uhlmann
| Società | Posizione | Inizio |
|---|---|---|
OMEICOS Therapeutics GmbH
 OMEICOS Therapeutics GmbH BiotechnologyHealth Technology OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany. | Fondatore | 01/01/2013 |
Formazione di Karen Uhlmann
| Freie Universität Berlin | Graduate Degree |
| Humboldt-Universität zu Berlin | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 1 |
|---|---|
OMEICOS Therapeutics GmbH
OMEICOS Therapeutics GmbH BiotechnologyHealth Technology OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany. | Health Technology |
- Borsa valori
- Insiders
- Karen Uhlmann
